Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Abstract

ABSTR AC TBreast carcinoma with pulmonary metastasis can be treated locally or systemically. Following primary tumour resection patients with isolated, completely resectable pulmonary nodules and definite functional operability can be offered lung metastasis resection. Following metastasectomy a median survival of 32 to 96.6 months can be achieved with corresponding five-year survival rates between 30.8 and 54.4 %. The procedure is associated with a mortality rate of 0 to 3 %. The most important independent prognostic factor for longterm survival is complete resection of all lung lesions. The configuration and pattern of metastasis as well as disease-free interval, hormone and HER2/neu receptor status also appear to influence prognosis, but are of lesser importance. Intrapulmonary recurrence of metastases may, after careful selection on a case-by-case basis, also be treated operatively. In some cases this is associated with a favourable long-term prognosis. Pulmonary metastasectomy should be the treatment of choice for selected patients with metastatic breast carcinoma. ZUSAMMENFASSUNG

Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases

“…In the present study, median survival from breast cancer diagnoses obviously varied by subtype, ranging from 8 months in triple-negative patients to 17 months in HR+/HER2+ patients. The median survival of all lung metastatic patients was 13 months, which was shorter than the 22 or 32 months reported in lung metastatic patients after treatment or metastasectomy in previous studies (Jin et al, 2018; Macherey et al, 2017; Welter et al, 2008). Although patients with lung metastases had poor prognoses, it was noteworthy that the 3-year and 5-year survival rate of patients was up to 33.9% and 17.8%, respectively.…”

“…Although patients with lung metastases had poor prognoses, it was noteworthy that the 3-year and 5-year survival rate of patients was up to 33.9% and 17.8%, respectively. Prior studies have shown that the 5-year survival rate of lung metastatic patients from the first pulmonary metastasectomy was 36% or 30.8% (Macherey et al, 2017; Welter et al, 2008). Few studies have been able to reveal the association between the survival rate of breast cancer patients with lung metastases and various molecular subtypes.…”

Nem tapintható tüdőgócok drót- és izotópjelölés segítségével történő minimálinvazív műtéti eltávolítása

“…A daganatos betegek kivizsgálása, szoros kontrollja, utánkövetése során a mellkas-CT-felvételen már kismé-retű áttétek is felismerésre kerülnek. Szoliter tumorok -mint colorectalis [4], emlő- [5], vese- [6], fej-nyaki [7] daganatok és sarcomák [8], tüdő áttétei -esetén is hatékony kezelési forma azok műtéti eltávolítása, ami növeli a betegek túlélését. Szintén elsődlegesen VATS-technikával történő eltávolításuk javasolt, általában atípusos, nem anatómiai reszekcióval [9].…”

Hydroxyl safflower yellow B combined with doxorubicin inhibits the proliferation of human breast cancer MCF‑7 cells

“…Modern medical research has revealed that the formation and growth of tumors are associated with cellular differentiation and apoptosis ( 6 ). Apoptosis-induced inhibition of tumor cell proliferation is currently an effective method for treating tumors ( 7 ). After numerous years of development, traditional Chinese medicine has identified a set of unique antitumor methods ( 8 ).…”